

Claims

1. Use of treosulphan and/or derivatives thereof for treating multiple sclerosis (MS).
2. Use according to claim 1 characterised in that the MS is a relapsing-remitting, primary progressive or secondary progressive MS.
3. Use according to claims 1 and 2 characterised in that the derivative is busulphan, dimethyl busulphan, pentasulphan or hepsulphan.
4. Use according to claims 1 to 3 characterised in that treosulphan or the derivative thereof is present in a form suitable for administering 1 to 10 g of treosulphan and/or treosulphan derivative per m² of body surface.
5. Use according to claim 4 for administering 3 to 9 or 5 to 8 g of treosulphan and/or treosulphan derivative per m² of body surface.
6. Use according to claims 1 to 5 characterised in that treosulphan and/or a derivative thereof is used in combination with one or several immunomodulatory effective substances.
7. Use according to claim 6 characterised in that the immunomodulatory effective substance is interferon- and/or glatiramer acetate.
8. Use according to claims 1 to 7 in the form of an infusion solution or an oral formulation.